公开(公告)号：EP2608787A1

公开(公告)日：2013-07-03

申请号：EP11758563.8

申请日：2011-08-23

申请人： Actelion Pharmaceuticals Ltd.

发明人： BOSS, Christoph ,  BROTSCHI, Christine ,  GATFIELD, John ,  GUDE, Markus ,  HEIDMANN, Bibia ,  SIFFERLEN, Thierry ,  WILLIAMS, Jodi T.

IPC分类号： A61K31/401 ,  A61K31/4025 ,  A61K31/535 ,  A61P39/00 ,  A61P25/30 ,  A61P25/00 ,  A61P3/00

摘要： The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.

摘要翻译： 本发明涉及式（I）的（S） - 脯氨酸磺酰胺化合物，其中R 1和R 2如说明书中所述，或其药学上可接受的盐，用于预防或治疗与以下相关的疾病或病症 食欲素系统。 本发明还涉及式（II）的（S） - 脯氨酸磺酰胺化合物作为药物，包含式（II）化合物的药物组合物，特别是它们用于预防或治疗与以下相关的疾病或病症的用途： 食欲素系统。

公开(公告)号：EP2429523A1

公开(公告)日：2012-03-21

申请号：EP10721851.3

申请日：2010-05-11

申请人： Actelion Pharmaceuticals Ltd.

发明人： AISSAOUI, Hamed ,  BOSS, Christoph ,  BROTSCHI, Christine ,  GATFIELD, John ,  GUDE, Markus ,  SIEGRIST, Romain ,  SIFFERLEN, Thierry ,  WILLIAMS, Jodi T.

IPC分类号： A61K31/426 ,  A61K31/427 ,  A61P3/00 ,  A61P5/00 ,  A61P25/00 ,  C07D277/14 ,  C07D417/04

CPC分类号： C07D277/14 ,  C07D417/04

摘要： The present invention relates to thiazolidin-4-one and [1,3]-thiazinan-4-one compounds of formula (I) wherein X, Y, R
3 and R
4 are as described in the description, or pharmaceutically acceptable salts thereof, for the prevention or treatment of diseases related to the orexin system. The present invention also relates to novel thiazolidin-4-one compounds of formula (II) and their use as pharmaceuticals, pharmaceutical compositions containing one or more compounds of formula (II), and especially their use as orexin receptor antagonists.

公开(公告)号：EP3152199A1

公开(公告)日：2017-04-12

申请号：EP15728640.2

申请日：2015-06-02

申请人： Actelion Pharmaceuticals Ltd.

发明人： SIEGRIST, Romain ,  HEIDMANN, Bibia ,  STAMM, Simon ,  GATFIELD, John ,  BEZENCON, Olivier

IPC分类号： C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D231/40 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D471/04 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P3/10 ,  A61P9/00 ,  A61P15/00 ,  A61P25/00 ,  A61P35/00

CPC分类号： C07D231/40 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D471/04

摘要： wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

摘要翻译： 其中X，Y，R 1，R 2，（R 4）n和（R 5）m如说明书中所定义，以及这些化合物的药学上可接受的盐。 这些化合物可用作钙T通道阻滞剂。

公开(公告)号：EP2288603A1

公开(公告)日：2011-03-02

申请号：EP09762141.1

申请日：2009-06-10

申请人： Actelion Pharmaceuticals Ltd.

发明人： AISSAOUI, Hamed ,  BOSS, Christoph ,  BROTSCHI, Christine ,  GATFIELD, John ,  KOBERSTEIN, Ralf ,  SIEGRIST, Romain ,  SIFFERLEN, Thierry ,  WILLIAMS, Jodi T.

IPC分类号： C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  A61P25/00 ,  A61P3/10

CPC分类号： C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14

摘要： The invention relates to tetrazole compounds of formula (I) wherein X, Y, Z, R
1 , R
2 and R
3 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.

公开(公告)号：EP2010167A2

公开(公告)日：2009-01-07

申请号：EP07735489.2

申请日：2007-04-12

申请人： Actelion Pharmaceuticals Ltd.

发明人： CLOZEL, Martine ,  GATFIELD, John ,  ROUX, Sebastien

IPC分类号： A61K31/145 ,  A61K31/4412 ,  A61K31/506 ,  A61K38/21 ,  A61K45/06 ,  A61P35/00

CPC分类号： A61K45/06 ,  A61K31/145 ,  A61K31/4412 ,  A61K31/506 ,  A61K38/217 ,  A61K2300/00

摘要： This present invention relates to the use of an endothelin receptor antagonist for the preparation of a medicament for the treatment of early stage idiopathic pulmonary fibrosis.